Metformin Use in Patients with Proteinuria and Reduced eGFR

Introduction to Metformin Dosing

The American Diabetes Association recommends metformin as first-line therapy for type 2 diabetes when eGFR is adequate, with a 1B recommendation for patients with T2D, CKD, and eGFR ≥30 mL/min/1.73 m² 4
The FDA drug label states that metformin is contraindicated when eGFR is below 30 mL/min/1.73 m², and initiation is not recommended when eGFR is between 30-45 mL/min/1.73 m², although this specific statement is not directly cited, the eGFR contraindication guideline is supported by 1

If eGFR ≥60 mL/min/1.73 m², use standard metformin dosing (up to 2550 mg/day in divided doses) and monitor eGFR at least annually 1
If eGFR 45-59 mL/min/1.73 m², continue the same dose in most patients, but consider dose reduction if conditions predisposing to lactic acidosis exist, and monitor eGFR every 3-6 months 1, 2
If eGFR 30-44 mL/min/1.73 m², reduce the dose to a maximum of 1000 mg/day and monitor eGFR every 3-6 months 1, 2
If eGFR <30 mL/min/1.73 m², discontinue metformin immediately due to substantially increased risk of lactic acidosis 3

Immediately discontinue metformin during acute situations regardless of baseline eGFR, such as serious infections, dehydration, acute heart failure, hospitalization for acute illness, acute kidney injury, or any hypoxic state 1
Temporarily discontinue metformin before procedures involving iodinated contrast if eGFR is 30-60 mL/min/1.73 m², or if the patient has a history of liver disease, alcoholism, or heart failure, and re-evaluate eGFR 48 hours after the procedure before restarting 1

Do not rely on serum creatinine alone for dosing decisions, always use eGFR, as creatinine can be misleading in certain patients 1
Do not continue metformin at any dose when eGFR <30 mL/min/1.73 m², as this is a hard contraindication with substantially increased risk of fatal lactic acidosis 3
Do not delay SGLT2 inhibitor initiation in patients with proteinuria and diabetes, as these agents provide cardiorenal protection independent of glycemic control and should be started immediately if eGFR permits 4, 3

Monitor eGFR every 3-6 months in patients with CKD (eGFR <60 mL/min/1.73 m²) and annually in those with normal renal function 1, 2
Monitor vitamin B12 levels after >4 years of metformin treatment, as metformin can cause B12 deficiency leading to macrocytic anemia or peripheral neuropathy 1